ImaRx’ Combo Treatment For Stroke To Wrap Up Phase I/II Trial By Mid-2008
This article was originally published in The Gray Sheet
Executive Summary
ImaRx is on track to complete enrollment in a Phase I/II dose escalation study by mid-2008 for its combo product SonoLysis, which uses ultrasound and microbubbles to treat acute ischemic stroke
You may also be interested in...
Combo Product Excitement: Large Players On Look-Out For Early-Stage Deals
Heightened corporate interest in innovative drug-delivery technologies offers greater opportunities for small device firms to attract larger company investment, venture capitalists say
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.